Pfizer 2010 Annual Report Download - page 118

Download and view the complete annual report

Please find page 118 of the 2010 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 120

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
QUARTER
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) FIRST SECOND THIRD FOURTH(a)
2009
Revenues $10,867 $ 10,984 $11,621 $ 16,537
Costs and expenses 6,510 7,456 7,457 13,354
Acquisition-related in-process research and development charges — 20 — 48
Restructuring charges and certain acquisition-related costs(b) 554 459 193 3,131
Income from continuing operations before provision for taxes on income 3,803 3,049 3,971 4
Provision for taxes on income 1,074 786 1,092 (755)
Income from continuing operations 2,729 2,263 2,879 759
Discontinued operations—net of tax 1 3 2 8
Net income before allocation to noncontrolling interests 2,730 2,266 2,881 767
Less: Net income attributable to noncontrolling interests 1 5 3 —
Net income attributable to Pfizer Inc. $ 2,729 $ 2,261 $ 2,878 $ 767
Earnings per common share—basic(c):
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Discontinued operations—net of tax — — — —
Net income attributable to Pfizer Inc. common shareholders $ 0.41 $ 0.34 $ 0.43 $ 0.10
Earnings per common share—diluted(c):
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.40 $ 0.34 $ 0.43 $ 0.10
Discontinued operations—net of tax — — — —
Net income attributable to Pfizer Inc. common shareholders $ 0.40 $ 0.34 $ 0.43 $ 0.10
Cash dividends paid per common share $ 0.32 $ 0.16 $ 0.16 $ 0.16
Stock prices
High $ 18.48 $ 15.60 $ 16.98 $ 18.99
Low $ 11.62 $ 12.75 $ 14.11 $ 16.07
(a) In accordance with our domestic and international fiscal year-ends, approximately two-and-a-half months of Wyeth’s U.S. operations and approximately
one-and-a-half months of Wyeth’s international operations are included in our consolidated financial statements for the quarter ended December 31,
2009. For additional information, see Note 2. Acquisition of Wyeth. The increase in revenues and costs and expenses in the fourth quarter of 2009
primarily reflects the results of Wyeth’s operations, as well as higher purchase accounting charges resulting from the Wyeth acquisition.
(b) Restructuring charges and certain acquisition-related costs includes restructuring charges recorded in the fourth quarter of 2009 related to our acquisition
of Wyeth.
(c) Earnings per share in fourth-quarter 2009 was impacted by the increased number of shares outstanding in comparison with prior 2009 quarters, resulting
primarily from shares issued to partially fund the Wyeth acquisition.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS
amounts may not agree to the total for the year.
116 2010 Financial Report